DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» CureVac
CureVac
Updated May 26, 2021 Cross-Border Industry Partnerships on COVID-19 Vaccines and Therapeutics Vaccines • Curevac O Celonic Wi
Curevac Announces Financial Results for the Second Quarter and First Half of 2021 and Provides Business Update
J&J Provides Early Hope for Single-Dose Covid-19 Vaccine
Nanomedicines to Deliver Mrna: State of the Art and Future Perspectives
Curevac Raises a Total of USD 640 Million in Private Financing Round
Curevac COVID Vaccine Let-Down Spotlights Mrna Design Challenges
Opportunities and Challenges in the Delivery of Mrna-Based Vaccines
Curevac Emerges with €35M Cancer Vaccine Endorsement
Curevac Announces Financial Results and Business Updates for the Fourth Quarter and Full-Year of 2020
Vaccine Manufacturing Collaborations
CRISPR Therapeutics and Casebia Collaborate with Curevac on Mrna for Gene-Editing Programs
Genmab and Curevac Enter Strategic Partnership to Develop Mrna-Based Antibody Therapeutics
Insight from NLP Analysis: COVID-19 Vaccines Sentiments on Social Media
Comparison and Analysis of Neutralizing Antibody Levels in Serum After Inoculating with SARS-Cov-2, MERS-Cov, Or SARS-Cov Vaccines in Humans
The Mrna Dollars Spread Beyond Moderna
Biopharmas Targeting Common Viral Denominators to Battle
Curevac Rides the Covid Wave
Dr C. Staehelin, Dr F. Jacquerioz with the Collaboration of Dr A. Allgöwer and Dr M
Top View
Curevac Appoints Klaus Edvardsen As Chief Development Officer
Curevac's Credibility Unravels Along with Its Covid-19 Vaccine
Genmab Announces Financial Results for the First Half of 2021
Ivt Mrna Therapies: Timelines
COVID-19 R&D-Based Pharma Industry's Innovative Partnership To
Genmab Announces Financial Results for the First Quarter of 2021
Covid Vaccine Flop Spotlights Mrna Design Challenges
Curevac Expands Cvncov Covid-19 Vaccine Candidate Clinical Trial Analyses to Include Phase 2B/3 Variant Specification and Efficacy Secondary Endpoint to Phase 2A
Novartis Signs Initial Agreement with Curevac to Manufacture COVID-19 Vaccine Candidate
2Nd International Mrna Health Conference PROGRAM November 11-12, 2014 • Cambridge, Massachusetts, U.S.A
Curevac Provides Update on Phase 2B/3 Trial of First-Generation COVID-19 Vaccine Candidate, Cvncov
Celonic and Curevac Announce Agreement to Manufacture Over 100 Million Doses of Curevac’S COVID-19 Vaccine Candidate, Cvncov
United States Securities and Exchange Commission Form
Industry Partnerships on COVID-19 Vaccines, Therapeutics and Diagnostics
21-12 How COVID-19 Vaccine Supply Chains Emerged in the Midst of a Pandemic
COVID Vaccine Chart Updated July 2, 2021
Curevac Appoints Dr. Franz-Werner Haas As Chief Executive Officer and Dr
Genmab and Curevac Enter Strategic Partnership to Develop Mrna-Based Antibody Therapeutics
Nanomaterial Delivery Systems for Mrna Vaccines
GSK and Curevac Announce Strategic Mrna Technology Collaboration
Working Together to Fight Covid-19: Vaccine Manufacturing Collaborations
Synthetic Messenger RNA-Based Vaccines: from Scorn to Hype
Curevac Receives Regulatory Approval from German and Belgian Authorities to Initiate